Plain-English translation of NCT07439887 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new gene therapy called RTx-021, which is injected directly into the eye to treat Stargardt disease. The medication works by delivering a special gene that helps remaining cells in the retina respond to light in a new way. Researchers will test three different dose levels to find the safest and most effective amount.
Stargardt disease causes progressive vision loss and currently has no cure or approved treatments. This trial exists to see whether this new gene therapy approach can safely help restore vision in people living with this condition.
You likely qualify if…
You likely don't qualify if…
You would receive a single injection of the gene therapy directly into your study eye during an office procedure. After treatment, you would have frequent follow-up visits over the first 12 months to monitor safety and any changes in vision, then continue with less frequent visits for a total of 5 years. The study involves eye exams, imaging tests, and vision assessments to track how well the treatment works.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States